α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls

Suaad Abd Elhadi, Jessica Grigoletto, Maura Poli, Paolo Arosio, David Arkadir, Ronit Sharon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.

Original languageAmerican English
Pages (from-to)2426-2436
Number of pages11
JournalAnnals of Clinical and Translational Neurology
Volume6
Issue number12
DOIs
StatePublished - 1 Dec 2019

Bibliographical note

Publisher Copyright:
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

Fingerprint

Dive into the research topics of 'α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls'. Together they form a unique fingerprint.

Cite this